Cite
HARVARD Citation
Datta, J. et al. (n.d.). Longitudinal follow-up of a prospective phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma reveals distinct patterns of survivorship. HPB. pp. S58-S59. [Online].